Aethlon Medical, Inc.

  • Home
  • The Hemopurifier®
    • The Hemopurifier® in Infectious Disease
    • The Hemopurifier® in Cancer
    • Resources
  • About
    • Overview
    • Exosome Sciences, Inc.
    • Executive Team
    • Board of Directors
    • Scientific Advisory Board
    • Contact Us
  • News & Media
    • Press Releases
    • Presentations
    • Events
    • Outside Media
  • Investors
    • Overview
    • Corporate News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
    • IRS Form 8937
News & Media

News & Media

  • Press Releases
  • Presentations
  • Events
  • Outside Media

Press Releases

Jan 22, 2020

Aethlon Medical Announces Completion of $3.77 Million Registered Direct Offering

Jan 17, 2020

Aethlon Medical Announces $3.77 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dec 17, 2019

Aethlon Medical Announces Closing of $5 Million Public Offering

Dec 13, 2019

Aethlon Medical Announces Pricing of $5 Million Public Offering

Nov 1, 2019

Aethlon Medical Announces Second Quarter Financial Results and Provides Corporate Update

Oct 29, 2019

Aethlon Medical To Release Second Quarter Financial Results and Host Conference Call on November 1, 2019

Oct 14, 2019

Aethlon Announces Reverse Stock Split

Oct 7, 2019

Aethlon Medical Announces FDA Approval Of IDE For Oncology Indications

Oct 3, 2019

Aethlon Medical Receives Extension from Nasdaq to Regain Compliance with Continued Listing Requirements

Sep 24, 2019

Aethlon Announces Collaboration to Identify Exosomes Involved in Cancer Progression and Treatment Resistance

    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • ...18
    • Facebook
    • Twitter
    • Linkedin
    • YouTube
    Privacy Policy Disclaimer Sitemap
    © 2021 Aethlon Medical, Inc. All Rights Reserved.